Lipid monitoring
Lipid monitoring has been studied in 2 papers since 2026: 1 observational study in people, 1 review; 2 in the past year. The newest paper, Sep 15, 2026: “A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction”.
2 papers study it4 findingsUpdated
See all 2 papers on lipid monitoring
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“extending monitoring intervals to 16-24 months were not associated with higher risks of mortality or CVD risk compared to 2-8 months”
2 of its findings point the other way.
- 1 lab in 1 country
- 2 findings against
- Funders: Amgen and 7 more
- 4 of 4 findings with company ties
- Humans1
What did studies of lipid monitoring find?
2Studies of lipid monitoring measured 2 outcomes: cardiovascular disease and mortality.
Cardiovascular disease
no changein humans1HR 1.002
1 study
Cardiovascular disease
no changein humans1HR 1.002
Lipid monitoring was not clearly linked with cardiovascular disease in humans (HR 1.002, 95% CI 0.846–1.187).
“extending monitoring intervals to 16-24 months were not associated with higher risks of mortality or CVD risk compared to 2-8 months”
HumansT2DM without prior CVD; baseline LDL-C <1.8 mmol/L; compared with monitoring every 2-8 monthsEvery 16-24 months
Diabetes research and clinical practice
Mortality
no changein humans1HR 1.094
1 study
Mortality
no changein humans1HR 1.094
Lipid monitoring was not clearly linked with mortality in humans (HR 1.094, 95% CI 0.948–1.263).
“extending monitoring intervals to 16-24 months were not associated with higher risks of mortality or CVD risk compared to 2-8 months”
HumansT2DM without prior CVD; baseline LDL-C <1.8 mmol/L; compared with monitoring every 2-8 monthsEvery 16-24 months
Diabetes research and clinical practice
What is lipid monitoring linked with?
2Studies link lipid monitoring with 2 measures: cardiovascular disease and mortality.
Cardiovascular disease
upin humans1HR 1.06
1 study
Cardiovascular disease
upin humans1HR 1.06
Lipid monitoring is associated with cardiovascular disease in humans (HR 1.060, 95% CI 1.017–1.105).
“monitoring every 9-15 months was associated with higher risks of mortality and CVD compared to 2-8 months”
HumansT2DM without prior CVD; baseline LDL-C ≥2.6 mmol/L; compared with monitoring every 2-8 monthsEvery 9-15 months
Diabetes research and clinical practice
Mortality
upin humans1HR 1.154
1 study
Mortality
upin humans1HR 1.154
Lipid monitoring is associated with mortality in humans (HR 1.154, 95% CI 1.069–1.245).
“monitoring of the lipid profile every 16-24 months was associated with higher mortality risk compared to monitoring every 2-8 months”
HumansT2DM without prior CVD; baseline LDL-C 1.8-2.59 mmol/L; compared with monitoring every 2-8 monthsEvery 16-24 months
Diabetes research and clinical practice